Drug intelligence / Profile preview

acetaminophen + isometheptene mucate + dichloralphenazone

Development stage
Discontinued
Lead developer
Galt Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Replaced original description with the provided description, preserving markdown and escaping double quotes and newlines: "**Acetaminophen + isometheptene mucate + dichloralphenazone** is a combination pharmaceutical product formerly approved and widely used for the acute treatment of tension headaches, vascular headaches, and migraines. It consists of three active ingredients: - **Acetaminophen**: a non-salicylate analgesic and antipyretic that increases the pain threshold, providing general headache relief. - **Isometheptene mucate**: a sympathomimetic amine that causes vasoconstriction of dilated cranial and cerebral blood vessels, reducing vascular headache symptoms. - **Dichloralphenazone**: a sedative that diminishes the emotional response to pain, enhancing overall symptomatic relief. The product was frequently used for acute headache episodes, particularly migraines, but has been discontinued in the US due to regulatory concerns regarding the unapproved status of isometheptene mucate and dichloralphenazone, not for safety or efficacy issues. Some compounded versions may still be available in limited circumstances[1][2][3][4][5][6][7][8]."

Brand names
MidrinAmidrineMigratineNodolorProdrin
Other names
acetaminophen / dichloralphenazone / isometheptene mucateisometheptene-dichloralphenazone-acetaminophenisometheptene mucate, dichloralphenazone and acetaminophen
02

Targets

AR (Adrenergic receptors)COXGABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on acetaminophen + isometheptene mucate + dichloralphenazone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetaminophen + isometheptene mucate + dichloralphenazone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call